首页/数据集/Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

NIAID Data Ecosystem2026-03-11 收录

结直肠癌靶向治疗

肿瘤临床试验

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2297402 数据链接链接失效反馈

官方服务：

资源简介：

This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

应用场景：

创建时间：

2019-07-15

结直肠癌靶向治疗

临床疗效评估

Primary objectives: The main objective to the trial is response rate. Primary endpoint is to evaluate response rate. Secondary endpoints are to evaluate and determine progressionfree survival, time to

NIAID Data Ecosystem80

Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer

生物标志物预测

结直肠癌靶向治疗

This study evaluates the relationship of biomarker expression and efficacy of bevacizumab plus chemotherapy in patients with unresectable/metastatic colorectal cancer. Before the treatment, the invest

NIAID Data Ecosystem60

Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study

儿童鼻咽癌治疗

肿瘤临床试验

This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy uses high-ener

DataCite Commons2025-06-01 更新50

The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer

结直肠癌靶向治疗

肿瘤生物标志物

Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer and explore some biomarkers that relate to target therapy.

NIAID Data Ecosystem80

Design and Synthesis of a 2‑Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy

CDK8抑制剂

结直肠癌靶向治疗

CDK8 is a transcriptional cyclin-dependent kinase and considered as a potential target in colon cancer therapeutics. Here, a novel selective CDK8 inhibitor was identified against colon cancer in vivo.

Figshare60

Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.

资源简介：

相关数据集